Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Potentiation of neutrophil extracellular trap (NET) release is one mechanism by which
antiphospholipid antibodies (aPL Abs) effect thrombotic events in patients with antiphospholipid …

Objective While endothelial dysfunction has been implicated in the widespread thromboinflammatory
complications of COVID‐19, the upstream mediators of endotheliopathy remain, for …

Antiphospholipid antibodies, present in one-third of lupus patients, increase the risk of
thrombosis. We recently reported a key role for neutrophils—neutrophil extracellular traps (NETs), …

Objectives Patients with antiphospholipid syndrome (APS) are at risk for subclinical endothelial
injury, as well as accelerated atherosclerosis. In the related disease systemic lupus …

Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombotic arterial and
venous occlusions. At the same time, lung histopathology often reveals fibrin-based …

Objective Defibrotide is a heterogenous mixture of polyanionic oligonucleotides currently
approved for treatment of transplant‐associated venoocclusive disease. While defibrotide has …

Ginger is known to have antiinflammatory and antioxidative effects and has traditionally
been used as an herbal supplement in the treatment of various chronic diseases. Here, we …

Neutrophil-mediated activation and injury of the endothelium play roles in the pathogenesis
of diverse disease states ranging from autoimmunity to cancer to COVID-19. Neutralization …

Antiphospholipid syndrome (APS) is a leading acquired cause of thrombotic events, with a
notable tendency to promote thrombosis in vascular beds of all sizes, including both arterial …